CN111671744A - Application of myricetin in preparation of medicine for treating schistosomiasis - Google Patents
Application of myricetin in preparation of medicine for treating schistosomiasis Download PDFInfo
- Publication number
- CN111671744A CN111671744A CN202010130233.9A CN202010130233A CN111671744A CN 111671744 A CN111671744 A CN 111671744A CN 202010130233 A CN202010130233 A CN 202010130233A CN 111671744 A CN111671744 A CN 111671744A
- Authority
- CN
- China
- Prior art keywords
- myricetin
- schistosoma japonicum
- application
- schistosomiasis
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 235000007743 myricetin Nutrition 0.000 title claims abstract description 73
- 229940116852 myricetin Drugs 0.000 title claims abstract description 73
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 201000004409 schistosomiasis Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title description 5
- 241000242677 Schistosoma japonicum Species 0.000 claims abstract description 37
- 241000242678 Schistosoma Species 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims description 20
- 235000013601 eggs Nutrition 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000017448 oviposition Effects 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 2
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 abstract description 24
- 229960002957 praziquantel Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 17
- 208000009434 Schistosomiasis japonica Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 8
- 201000006675 intestinal schistosomiasis Diseases 0.000 abstract description 8
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 230000000749 insecticidal effect Effects 0.000 abstract description 4
- 229940121657 clinical drug Drugs 0.000 abstract description 3
- 238000010172 mouse model Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 19
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 5
- 241000754688 Cercaria Species 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001595 mastoid Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000019532 Schistosoma japonicum infectious disease Diseases 0.000 description 2
- 241000242680 Schistosoma mansoni Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- -1 flavonol compound Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001758 mesenteric vein Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000565675 Oncomelania Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001442514 Schistosomatidae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000037971 neglected tropical disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of myricetin in preparing a medicament for treating schistosomiasis. The invention discovers that the myricetin has good schistosome disinsection effect no matter in vivo or in vitro and improves the hepatic fibrosis of the mouse infected by the schistosoma japonicum through in vitro observation of the schistosoma japonicum anti-schistosoma japonicum effect of the myricetin and establishment of a mouse model infected by the schistosoma japonicum for in vivo experiments. In addition, the insecticidal effect of myricetin is equivalent to the positive drug praziquantel, and the myricetin can replace the application of myricetin in schistosomiasis japonica, provides possibility for avoiding clinical drug resistance, and has a wide application prospect.
Description
Technical Field
The invention relates to the technical field of biology, in particular to the technical field of prevention and treatment of schistosomiasis japonica, and more particularly relates to a new application of myricetin in preparation of drugs for treating schistosomiasis japonica.
Background
Schistosomiasis is prevalent in 78 countries and regions worldwide as a neglected tropical disease, with 7.79 million people threatened, with a conservative estimate of about 2.30 million people infected, with 1.2 million people symptomatic, resulting in nearly 30 million deaths annually in africa in the south of sahara alone from schistosomiasis. Schistosomiasis is a parasitic disease caused by a parasite of the genus schistosoma, and there are mainly six human-related species of schistosomiasis organisms, of which schistosoma mansoni, schistosoma japonicum and schistosoma japonicum are the most prevalent. The average life of the schistosoma japonicum in the host is 3-10 years, and the living time can even be as long as 40 years in some cases. Although schistosoma japonicum cannot proliferate in the final host, it can produce large numbers of eggs deposited in the liver or other organs, the mature female worms will lay hundreds and thousands of eggs every day, long term parasitism and large numbers of eggs cause infection and disease transmission.
In the absence of an effective vaccine, chemotherapy is an important means of preventing and treating schistosomiasis today. The first choice of drug currently used in the clinic is praziquantel, which is effective against all species of schistosomes infecting humans and has low toxic side effects. However, the application of praziquantel has many limitations, and the praziquantel is only effective on early childhood insects (3-6 h) and adults just penetrating into the skin, has weak effect on the childhood insects, has no preventive effect, and is a big problem in blood control work due to repeated infection of a treated person after treatment. Meanwhile, because the long-term large-scale repeated use of the praziquantel in the circulation area easily causes the drug resistance of schistosoma, British scholars adopt sub-dose praziquantel to treat infected mice in a laboratory to induce schistosoma mansoni praziquantel resistant strains, so that the search for an effective drug capable of replacing the praziquantel is very urgent.
Myricetin of formula C15H10O8Is a natural flavonol compound widely existing in many natural plants, fruits and vegetables, and has the functions ofThe compound has wide pharmacological activities including antioxidant, antitumor, anti-inflammatory, antimicrobial, antiallergic, cardiovascular and neuron protecting, and has little toxic and side effects, and no toxic effect or death is found when 1000mg/kg myricetin is injected into the abdominal cavity of a mouse. In addition, it has been shown that dihydromyricetin can reduce CCl4Protective action of induced mouse liver fibrosis lesion (Kuang plement, Rogming, Jialei, et al. dihydromyricetin on lipid peroxidation injury of liver fibrosis rat [ J]Chinese medicine, 2009, 6(18): 26-28.); dihydromyricetin has obvious therapeutic action on schistosomiasis hepatic fibrosis (Zhuilong, Wangjunjie, Chenmeizi, et al. Experimental research of dihydromyricetin for treating schistosomiasis hepatic fibrosis [ J]Chinese clinical pharmacology and therapeutics, 2010,15(4): 381-384.). At present, only dihydromyricetin is found to have a treatment effect on organ pathological injury of schistosomiasis-induced hepatic fibrosis after schistosomiasis infection, but no report is found on the effect of myricetin in treating schistosomiasis and the effect of myricetin in schistosomiasis-induced hepatic fibrosis.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a new application of myricetin in preparing a medicament for treating schistosomiasis.
The above object of the present invention is achieved by the following technical solutions:
according to the invention, firstly, the effect of resisting schistosoma japonicum in vitro is observed in vitro, the myricetin is found to have a good effect of resisting schistosoma japonicum in vitro, a schistosoma japonicum infected mouse model is further established for an in vivo experiment, the myricetin is found to have a good schistosoma japonicum disinsection effect no matter inside and outside a body, the myricetin can effectively inhibit the oviposition amount of the schistosoma japonicum, and the inhibition effect is not obviously different from that of a positive drug praziquantel, so that the myricetin and the praziquantel can effectively reduce the liver egg deposition, and the myricetin can reduce the infection of pathogenic polypide from the source, thereby playing a role in treating schistosomiasis. Meanwhile, the myricetin is found to have the improvement effect on the liver fibrosis of mice infected with schistosoma japonicum. The insecticidal effect of myricetin is equivalent to that of a positive drug praziquantel, and the myricetin can replace the application of myricetin in schistosomiasis japonica, provides possibility for avoiding clinical drug resistance and has a great application prospect.
Therefore, the following applications of myricetin are all within the scope of the present invention:
application of myricetin in preparing medicine for treating schistosomiasis is provided.
Application of myricetin in preparing medicine for inhibiting schistosomiasis is provided.
Application of myricetin in preparation of medicine for inhibiting oviposition of schistosome
Application of myricetin in preparing medicine for reducing the load of eggs of schistosome and eggs of liver in host infected by schistosome is provided.
Application of myricetin in preparing medicine for improving liver disease injury caused by schistosome is provided.
Preferably, the pathological injury to the liver is liver fibrosis.
Preferably, the schistosoma japonicum is schistosoma japonicum.
The invention also provides a medicament for treating schistosomiasis, which contains myricetin.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides an application of myricetin in preparing a medicament for treating schistosomiasis. The research of the invention finds that the myricetin can have good anti-schistosoma japonicum effect, and the in-vivo experimental result proves that the myricetin obviously reduces the load of eggs and liver eggs in mice infected with schistosoma japonicum, and obviously improves the liver fibrosis lesion of the mice; the myricetin can be used for treating schistosomiasis japonica in the early stage, and has a treatment and improvement effect on liver pathological injury caused by the attack of schistosomiasis japonica in the later stage. Moreover, the myricetin has the effect equivalent to that of the positive drug praziquantel, can replace the application of praziquantel in the diseases, and provides possibility for avoiding clinical drug resistance.
Drawings
FIG. 1 is the chemical structural formula of myricetin and its influence on Schistosoma japonicum; FIG. 1A is the structure of myricetin compound, and FIG. 1B is the survival curve of Schistosoma japonicum after the myricetin with different concentrations acts.
FIG. 2 is a scanning electron micrograph of Schistosoma japonicum after the action of myricetin (A, male worm; B, female worm; Oral sucker; ventral sucker; tegument; gynecophoral gland).
FIG. 3 is H & E staining pattern of mouse liver infected with Schistosoma japonicum after myricetin action.
FIG. 4 is a Masson staining pattern of the liver of mice infected with Schistosoma japonicum after myricetin action.
FIG. 5 shows the expression of factors related to liver fibrosis of mice infected with Schistosoma japonicum after myricetin action.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. The reagents, methods and apparatus employed in the present invention are conventional in the art, unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
Example 1 in vitro insecticidal Effect assay of Myricetin
The preparation of the medicine comprises the following steps: myricetin was formulated with DMSO to a final concentration of 10 μ M.
Construction of a Schistosoma japonicum infected New Zealand rabbit model:
placing Schistosoma japonicum positive Oncomelania in 12-well plate at room temperature of 25 + -1 deg.C, adding dechlorinated water to 2/3, placing under incandescent lamp, irradiating for 2h to escape cercaria, removing abdominal skin, moistening skin with dechlorinated water, sticking cover glass carrying counted cercaria on the dehaired skin, and removing the glass after 20 min. New Zealand rabbits are infected with 1000-1200 cercaria/rabbit.
New Zealand rabbit at 8 weeks after infection, taking blood from heart, killing by air embolism, dissecting, collecting Schistosoma japonicum fixed in inferior mesenteric vein and hepatic portal veinAdults, bodies of which were washed with physiological saline and transferred to 24-well plates, 3 pairs of adults per well per 1ml of complete medium (RPMI 1640 medium containing 100U/ml penicillin, 100. mu.g/ml streptomycin, and 10% heat-inactivated serum) at 37 ℃ with 5% CO2After the incubation in a thermostat for 4 hours, adding myricetin (300-1000 mu M) with different concentrations, simultaneously taking 100 mu M praziquantel and 1% DMSO as a positive control and a negative control respectively, and observing the survival state of the polypide under an inverted microscope when incubating for 24, 48 and 72 hours; the results are shown in FIG. 1.
The results in FIG. 1 show that the negative control group survived 80% after 96h in vitro culture; all the insects die when acted by positive control medicament praziquantel or myricetin (1000 mu M) for 8 h. Myricetin acting on 24h IC of schistosoma japonicum50At 600 μ M, it was time and dose dependent on killing of adults in vitro. Collecting Schistosoma japonicum adults with a lethal dose of myricetin for 24h, and observing the damage condition of the schistosoma japonicum adults by a scanning electron microscope and a transmission electron microscope; the results are shown in FIG. 2.
FIG. 2 shows the result of normal worm sucking disc margin, male skin layer with spongy fold ridges and pits, and single hair ball shaped sensory papillae distributed on the body skin layer; the normal female body wall is in a regular strip shape, and depressions are distributed on the normal female body wall and are lined with sensory papillae. After the action of myricetin, the sucking discs of the male insect mouths and the abdomens are inwards sunken, the edges are swelled, the surface is irregularly contracted, the disc-shaped bulges are deformed, the folds on the surface of the cortex layer are arranged in a disordered way, the cilia on the mastoid are lost, and the mastoid is felt to be collapsed or disappear; the female insect mouth abdominal sucker edge is necrotic and burst, with the adhesion of a block, the cortical fold ridges in the middle section and the tail part of the insect body are fused into small pieces, and the mastoid is reduced, which shows that the myricetin can damage the integrity of the schistosoma japonicum body wall, and the myricetin has good function of resisting the schistosoma japonicum adult.
Example 2 Myricetin is effective in reducing the number of adult mice infected with Schistosoma japonicum and improving liver fibrosis lesions
1. Japanese blood fluke infected mouse model establishment
(1) Balb/c mice were randomly divided into four groups, namely a normal control group (ctrl), an infected group (infested), a praziquantel-treated group (pzq-treated) and a myricetin-treated group (me-treated), with 8 mice per group.
(2) Except for the normal control group, the other mice were infected with 30. + -. 2 pieces of Schistosoma japonicum cercaria as described above.
(3) 36-42 days after infection, the praziquantel treatment group and the myricetin treatment group respectively irrigate the stomach of the mice with 500mg/kg of praziquantel and 250mg/kg of myricetin (prepared by 0.9 percent of normal saline) every day, and irrigate the stomach of the other two groups with normal saline with the same volume.
2. And (3) after 7 weeks of schistosoma japonicum infection, carrying out orbital bleeding after anesthetizing a mouse by intraperitoneal injection of pentobarbital sodium, perfusing the heart to collect adults of the hepatic portal vein and the mesenteric vein, rapidly collecting liver tissues, and preserving the tissues according to different experimental requirements after weighing. All collected worms were placed in a 60mm dish of physiological saline, and the total number of worms, female and male worms, were counted under a scope. Shearing central lobe of partial liver of each group of mice, weighing, placing in an EP tube, shearing, adding 4% potassium hydroxide solution, shaking in a constant temperature shaking table at 37 ℃ overnight until liver tissue is completely digested, centrifuging 1500g for 5min, removing upper layer liquid, and diluting lower layer precipitate with normal saline to 1 ml. Taking 10 mu l of the resuspension, tabletting, counting under a microscope, and repeating for 5-7 times. Calculating the number of worm eggs contained in each gram of liver tissue; the results are shown in Table 1:
TABLE 1 adult mouse infected with Schistosoma japonicum and the liver worm egg load after myricetin administration
The results in Table 1 show that myricetin can significantly reduce the adult load of mice, and little adult is observed in the praziquantel-treated group, which indicates that the in vivo insecticidal effect of praziquantel is more effective than myricetin. Interestingly, the result of the liver worm egg load of each group of mice shows that both praziquantel and myricetin can effectively inhibit the egg laying amount of schistosoma japonicum, and the inhibition effect has no obvious difference between the two drugs, which indicates that myricetin and praziquantel can effectively reduce the deposition of liver worm eggs.
3. Carrying out conventional paraffin section on the liver tissue, and observing pathological injury conditions of the liver tissue of the mouse by H & E and Masson staining; the results are shown in FIGS. 3 and 4.
FIG. 3 is a graph showing the H & E results of the livers of the mice in each group after myricetin action, and it can be seen from the graph that the lobules of the livers of the normal group under the microscope are complete in structure, the central veins and the radioactive liver cell cords can be seen, and the small bile ducts and fibrous tissue hyperplasia can not be seen in the areas of the junction and the periphery. After infection, the liver can be seen with worm egg deposition, a large amount of inflammatory cells infiltrate around the worm eggs, and collagen deposition is accompanied, typical worm egg granuloma is formed and is in diffuse distribution, and the granuloma area of the myricetin or praziquantel treatment group is obviously reduced compared with that of the infection group.
FIG. 4 is a Masson result graph of the livers of each group of mice after the action of myricetin, the livers of the infected group of mice have a large amount of fresh collagen fibers deposited around granuloma and are distributed in liver tissues in a diffused manner, and liver fibrosis of the myricetin or praziquantel treatment group is obviously improved, which shows that myricetin can effectively improve liver pathological injury caused by schistosoma japonicum.
4. Liver tissues of each group of mice are extracted with Lysis buffer (Thermo Fisher) and TRIzol (Thermo Fisher) reagents to obtain total tissue protein and total RNA, and Western blot and RT-qPCR are used for detecting the expression of fibrosis-related molecules such as alpha-SMA, Collagen I and Collagen IV.
The primers used were as follows:
α-SMA:
F:5’-CACAGCCCTGGTGTGCGACAAT-3’;
R:5’-TTGCTCTGGGCTTCATCCCCCA-3’;
Collagen I:
F:GGAGACAATGGAGACCGAAA-3’;
R:5’-CGACCAATTAGGGCTTGTGT-3’;
Collagen IV:
F:5’-ATGCCCTTTCTCTTCTGCAA-3’;
R:5’-GAAGGAATAGCCGATCCACA-3’;
the results are shown in FIG. 5, and FIG. 5 is a graph showing the effect of myricetin on the expression of factors related to liver fibrosis of mice infected with Schistosoma japonicum, and it can be seen from the graph that myricetin can effectively reverse the expression of alpha-SMA, Collagen I and Collagen IV induced by Schistosoma japonicum infection (5A, RT-qPCR results; 5B, 5C, Western blot results).
Among the results of the detection, the quantitative results are expressed as mean ± Standard Deviation (SD). All data were statistically analyzed using SPSS 19.0(SPSS Inc, New York, USA). Differences between groups were analyzed using one-way analysis of variance (ANOVA). All histograms were plotted by GraphPad Prism 7.0 (GraphPad Software, San Diego, USA). P <0.05, P <0.01, P < 0.001.
The above description is intended to describe in detail the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the claims of the present invention, and all equivalent changes and modifications made within the technical spirit of the present invention should fall within the scope of the claims of the present invention.
Claims (8)
1. Application of myricetin in preparing medicine for treating schistosomiasis is provided.
2. Application of myricetin in preparing medicine for inhibiting schistosomiasis is provided.
3. Application of myricetin in preparing medicine for inhibiting oviposition of schistosome is provided.
4. Application of myricetin in preparing medicine for reducing the load of eggs of schistosome and eggs of liver in host infected by schistosome is provided.
5. Application of myricetin in preparing medicine for improving liver disease injury caused by schistosome is provided.
6. Use according to claim 5, wherein the pathological damage of the liver is liver fibrosis.
7. The use of any one of claims 1 to 6, wherein the schistosoma japonicum is Schistosoma japonicum.
8. A medicine for treating schistosomiasis is characterized by containing myricetin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010130233.9A CN111671744B (en) | 2020-02-28 | 2020-02-28 | Application of myricetin in preparation of medicine for treating schistosomiasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010130233.9A CN111671744B (en) | 2020-02-28 | 2020-02-28 | Application of myricetin in preparation of medicine for treating schistosomiasis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111671744A true CN111671744A (en) | 2020-09-18 |
CN111671744B CN111671744B (en) | 2023-03-21 |
Family
ID=72433219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010130233.9A Active CN111671744B (en) | 2020-02-28 | 2020-02-28 | Application of myricetin in preparation of medicine for treating schistosomiasis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111671744B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052868A1 (en) * | 2002-09-12 | 2004-03-18 | William Asiedu | Composition treating for AIDS and associated conditions |
WO2013063613A2 (en) * | 2011-10-28 | 2013-05-02 | University Of Maryland | Methods and compositions related to intracellular neutralization by igg |
CN109758449A (en) * | 2019-02-28 | 2019-05-17 | 天津国际生物医药联合研究院 | Myricetin is preparing the application in the drug for treating pulmonary fibrosis disease |
-
2020
- 2020-02-28 CN CN202010130233.9A patent/CN111671744B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052868A1 (en) * | 2002-09-12 | 2004-03-18 | William Asiedu | Composition treating for AIDS and associated conditions |
WO2013063613A2 (en) * | 2011-10-28 | 2013-05-02 | University Of Maryland | Methods and compositions related to intracellular neutralization by igg |
CN109758449A (en) * | 2019-02-28 | 2019-05-17 | 天津国际生物医药联合研究院 | Myricetin is preparing the application in the drug for treating pulmonary fibrosis disease |
Non-Patent Citations (5)
Title |
---|
ISABELLE KUHN等: "Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD+ catabolizing enzyme", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
ROBSON XAVIER FARIA等: "Molluscicidal activity of Manilkara subsericea (Mart.) dubard on Biomphalaria glabrata (Say, 1818)", 《ACTA TROPICA》 * |
方会龙等: "二氢杨梅素治疗血吸虫病肝纤维化的实验研究", 《中国临床药理学与治疗学》 * |
李杜等: "二氢杨梅素的肝病药理机制研究进展", 《中西医结合肝病杂志》 * |
王贵强等: "《感染科诊疗常规》", 30 November 2012, 中国医药科技出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN111671744B (en) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI558405B (en) | Cicada active material, a preparation method thereof, a pharmaceutical composition comprising the same and a use thereof | |
Ali et al. | Schistosoma mansoni: Antiparasitic effects of orally administered Nigella sativa oil and/or Chroococcus turgidus extract | |
Li et al. | Fungicidal efficacy of photodynamic therapy using methylene blue against Sporothrix globosa in vivo and in vivo | |
Maden et al. | Supernumerary limbs in the axolotl | |
El-Beshbishi et al. | Efficacy of artemisinin–naphthoquine phosphate against Schistosoma haematobium adult flukes: dose–effect relationship and tegumental alterations | |
CN111671744B (en) | Application of myricetin in preparation of medicine for treating schistosomiasis | |
Jiraungkoorskul et al. | Schistosoma mekongi: the in vitro effect of praziquantel and artesunate on the adult fluke | |
US20130171263A1 (en) | Snake Powder Extract For Treatment Of Cancer | |
West | Diseases of the organs of respiration v. 2 | |
El-Ashram | On Aeromonas hydrophila infection among cultured tilapias: a biological, histopathological and management study | |
CN108837029B (en) | Pharmaceutical composition for preventing and treating saprolegniasis of aquatic animals and preparation method thereof | |
Markley et al. | Deep scopulariopsosis of ulcerating granuloma type confirmed by culture and animal inoculation | |
CN106176747B (en) | Tacrine is preparing the application in treating treating echinococcosis | |
CN102836152B (en) | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis | |
CN106074564B (en) | Ursolic acid is preparing the application in anti-hydatid drugs | |
Mukherjee | Fish diseases in India, their causes and control measures-Winter school on recent advances in diagnosis and management of diseases in mariculture, 7th to 27th November 2002, Course Manual | |
Rosidah et al. | Potential of Aloe vera for treatment of infection with Aeromonas hydrophila bacteria on koi fry | |
CN116747218B (en) | Patchouli alcohol and patchouli alcohol compound antimalarial composition and application thereof in preparation of antimalarial protozoon drugs | |
CN1056407C (en) | Live bacteria preparation containing Bacillus subtilis and its application in treatment of burns | |
CN111760032B (en) | Composition for preventing and treating drug-resistant coccidiosis of chicken and preparation method and application thereof | |
Yadav et al. | Extensive myiasis infestation over a malignant lesion in maxillofacial region: Report of cases | |
Abdullah et al. | Evaluation study of Matricaria chamomilla extract toward pathogenic isolates of Candida | |
Masters | Essentials of tropical medicine | |
CN115737817A (en) | Application of tyrosine kinase inhibitor in preparation of echinococcosis treatment drug | |
Huang | Infectious and parasitic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |